Publication:
Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Simple item page
dc.contributor.authorsBeksac, Meral; Seval, Guldane Cengiz; Paydas, Semra; Tuglular, Tulin Firatli; Arslan, Onder; Goker, Hakan; Kaynar, Leylagul; Altuntas, Fevzi; Atalay, Figen; Teke, Havva Uskudar; Bolaman, Ali Zahit; Pehlivan, Mustafa; Sonmez, Mehmet; Demir, Ahmet Muzaffer; Topcuoglu, Pervin; Yilmaz, Mehmet; Kabukcu, Sibel Hacioglu; Albayrak, Murat; Yurttas, Nurgul Ozgur; Salihoglu, Ayse; Cakar, Merih Kizil; Gurman, Gunhan
dc.date.accessioned2022-03-10T18:00:07Z
dc.date.accessioned2026-01-11T17:15:59Z
dc.date.available2022-03-10T18:00:07Z
dc.date.issued2019
dc.identifier.doi10.1016/j.clml.2019.09.402
dc.identifier.eissn2152-2669
dc.identifier.issn2152-2650
dc.identifier.urihttps://hdl.handle.net/11424/222264
dc.identifier.wosWOS:000491229800399
dc.language.isoeng
dc.publisherCIG MEDIA GROUP, LP
dc.relation.ispartofCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectelotuzumab
dc.subjectimmunomodulatory drugs
dc.subjectMultiple myeloma
dc.titleElotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.endPageE243
oaire.citation.issue10
oaire.citation.startPageE242
oaire.citation.titleCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
oaire.citation.volume19

Files

Collections

Araştırma Çıktıları